Parallel Reviews Should Lead To Local Coverage, Coding Decisions, Firms Say
This article was originally published in The Gray Sheet
Executive Summary
Device makers say that for FDA and CMS parallel reviews to be successful, they must enable local coverage determinations and coding decisions, not just national coverage decisions.
You may also be interested in...
Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination
While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.
Breakthrough Reimbursement Proposals Percolate From FDA, Industry
As industry continues to nudge CMS to follow FDA's lead in making reforms that streamline the path to market for innovative new devices, the agencies are themselves floating solutions. All sides are thinking up strategies to rely on FDA's determination that a device meets certain "breakthrough" standards to trigger a streamlined path to data-conditioned reimbursement. But some in industry are concerned about an overemphasis on national, rather than local, coverage, and, in particular, the Medicare coverage-with-evidence-development process.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.